NCT02970747Completed
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
A Non-interventional Study of Carfilzomib (Kyprolis®) in Combination With Lenalidomide (Revlimid®) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone or Carfilzomib in Combination With Daratumumab (Darzalex®) and Dexamethasone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
The objective of this non-interventional study (NIS) is to evaluate patients' adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone or in combination with dexamethasone alone or in combination with daratumumab and dexamethasone in adult patients with multiple myeloma (MM) who have received at least one prior therapy in a real-life setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 359 (actual)
- First submitted
- 10 Nov 2016
- Start date
- 25 Oct 2016
- Primary completion date
- 26 Apr 2025
- Lead sponsor
- iOMEDICO AG
- Diseases
- Multiple myeloma
- NCT number
- NCT02970747
What you commit to
- Study type: Observational
- Participants enrolled: 359
- From 25 Oct 2016 to the primary completion date, 26 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindications according to the current SmPC for Kyprolis® (Carfilzomib)
Who the study is looking for
- Aged 18 years or older.
- Patients with MM who have received at least one prior therapy.
- Indication for treatment as assessed by the treating physician.
- Decision for second- or subsequent-line treatment with the combination therapy carfilzomib/ lenalidomide/ dexamethasone or carfilzomib/ dexamethasone or carfilzomib/ dexamethasone/ daratumumab
- Signed written informed consent.
- Criteria according to the current Summary of Product Characteristics (SmPC) for Kyprolis® (Carfilzomib)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centrum für Hämatologie und Onkologie Bethanien Coordinator of this site? Confirm its status | Frankfurt | Germany | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.